Cost Effectiveness of Enoxaparin in Acute ST-Segment Elevation Myocardial InfarctionThe ExTRACT–TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis In Myocardial Infarction 25) Study
Leo Marcoff, MD*,
Zugui Zhang, PhD*,
Wei Zhang, MS*,
Edward Ewen, MD*,
Claudine Jurkovitz, MD, MPH*,
Prisca Leguet, PharmD ,
Paul Kolm, PhD* and
William S. Weintraub, MD*,*
* Christiana Care Center for Outcomes Research, Christiana Care Health System, Newark, Delaware
Sanofi-Aventis, Paris, France
View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Cost-Effectiveness Plane for the 30-Day Analysis
Scatterplot of the joint distribution of cost and effectiveness differences in the cost-effectiveness plane for the 30-day analysis. UFH = unfractionated heparin.
|
|
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Cost-Effectiveness Plane and Acceptability Curve for the Lifetime Analysis
Scatterplot of the joint distribution of cost and effectiveness differences in the (A) cost-effectiveness plane and (B) acceptability curve for the lifetime analysis. ICER = incremental cost-effectiveness ratio; UFH = unfractionated heparin.
|
|
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Sensitivity Analysis
Sensitivity analysis showing the effect of the additional 10% to 40% increase or decrease of life-years gained (LYG) for enoxaparin compared with unfractionated heparin (UFH) on the incremental cost-effectiveness ratio (ICER). The black line indicates ICER in LYG; the fuschia line indicates ICER in quality-adjusted life-years (QALY) gained.
|
|
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Probabilistic Sensitivity Analysis
Contour plot of simulated distribution of mean differences in cost and effectiveness on the basis of (A) the probabilistic sensitivity analysis over a lifetime and (B) the cost-effectiveness acceptability curve. ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-years; UFH = unfractionated heparin.
|
|
|
